Biopharmaceuticals vectored in eukaryotic microalgae cells, for oral-mucosal delivery.
Bioproduction of recombinant immunotoxins (gen3 RITs), antimicrobial, antiviral and vaccine peptides, through our own multigenic, stable and highly productive microalgae cell lines.
USP by heterotrophic fermentation (mature technology) or by photoautotrophy (under validation).
DSP by controlled cellular deconstruction.
Galenic pharmacology: active delivery and controlled release by microalgae whole cells, purified organelles, fragments, or extracts.
Industrial extrapolation: manufacturing in commercial quantities, at reduced costs (factor 10-100 vs CHO), while respecting the quality requirements of the pharmaceutical industry.
Platform accessible to any biodrug producer, eventually extended to other ‘hostile’ molecules, to glycoproteins, monoclonal antibodies.